UniQure (QURE) Soars 6.67% on FDA Breakthrough Therapy Designation

UniQure (QURE) closed flat today, with the share price rising to its highest level since February 2025, marking an intraday gain of 6.67%.

UniQure's recent stock price surge can be attributed to several key developments. The FDA's designation of uniQure's AMT-130 as a Breakthrough Therapy for Huntington's disease has significantly boosted investor confidence. This designation is a major milestone, indicating the potential of AMT-130 to address a critical medical need, which has positively impacted the company's stock value.

Investor interest in uniQure has been notably high, as evidenced by the substantial premarket surge in the stock price. This surge reflects growing optimism about the company's prospects and its ability to deliver innovative therapies to the market.